ECDC regularly assesses new evidence on variants detected through epidemic intelligence, rules-based genomic variant screening or other scientific sources.
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
At the request of the Slovenian National Institute of Public Health (NIJZ), ECDC designed and facilitated an After-Action review (AAR), focusing on the response to the COVID-19 pandemic.
ECDC initiated a survey of EU/EEA countries to evaluate preparedness planning and risk mitigation initiatives implemented at the country level for people exposed to highly pathogenic avian influenza virus A(H5N1).
The aim of this survey was to review the expertise, capabilities and capacities for detection and characterisation of avian and other zoonotic influenza viruses in national influenza reference laboratories in the European Union/European Economic Area (EU/EEA), in members of the European Reference Laboratories for influenza (ERLINet), and in EU Enlargement policy countries.
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses, against hospitalisation due to COVID-19 and COVID-19 related deaths in resident populations ≥50 years of age, living in the community.
Overview of all the data available on the COVID-19 pandemic, including the The European Respiratory Virus Surveillance Summary (ERVISS) and variants of concern.